Mirati’s New CEO Clears Out Execs Ahead Of Key Filing And Readout
Keytruda Combo Data Next Week
Executive Summary
The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.
You may also be interested in...
How The Curtain Finally Closed On Ferring/Blackstone’s Gene Therapy Venture FerGene
Having failed to live up to its promising beginnings, FerGene, the gene therapy firm founded with the backing of Ferring and Blackstone to advance the former’s candidate for bladder cancer is back under the Swiss pharma's wing. However, doubts about its future and that of nadofaragene firadonavec remain.
Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data
The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.
Lumakras Sales A Highlight Of Amgen’s Mixed Q3
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.